



## ASX Announcement

16 May 2023

### BCAL APPOINTS DAVID DARLING AS ADVISOR

[BCAL Diagnostics Limited](#) (ASX:BDX) (BCAL or Company) an Australian-based biotechnology company is pleased to announce that it has appointed Mr David Darling as an Advisor to the Company.

David has had an extensive career working on the development, growth and international commercialisation of start-up and young companies.

For the past 19 years, David has been CEO of Pacific Edge, a NZX50 business focused on commercialising its bladder cancer diagnostics tests in global markets, particularly the USA. David has a background as a scientist, with a speciality in genetics, and has more than three decades experience in developing and commercialising life sciences and biotechnology products businesses. Prior to Pacific Edge, David held senior management positions with Fletcher Challenge.

David has strong governance and executive management experience and skills. He has served as a Director of Pacific Edge and its subsidiary businesses in New Zealand, Australia, Singapore and the USA and is a Board Director on a number of private business and organisation boards.

Jayne Shaw commented, *"we are delighted to bring David on as an advisor to BCAL. David took Pacific Edge from a start-up to a company dual listed on the NZX and ASX with a market capitalisation of just over NZ\$1billion, with 80 staff across four countries and 6000 shareholders. David's counsel will be of great value as we move towards commercialising the BCAL blood test for breast cancer, initially as an adjunct to mammography."*

To learn more about BCAL or to participate in BCAL's research, you can register your interest online at [www.bcaldiagnostics.com](http://www.bcaldiagnostics.com).

This ASX announcement has been approved for release by the Board of BCAL.

**ENDS**

For personal use only

### **About BCAL Diagnostics Limited (BCAL)**

BCAL Diagnostics Limited is an Australian biotechnology company committed to improved health outcomes for women. Over the past decade, BCAL has developed a non-invasive blood screening technology that is initially intended to be used alongside breast cancer screening methods, with results to date demonstrating 91% sensitivity and 80% specificity. The technology will initially complement current imaging technologies, such as the mammogram, while BCAL further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes BCAL has partnered with Precion Inc. to optimise protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions, commercialisation and market entry points. Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX:BDX). For more information: <https://www.bcaldiagnostics.com>

#### **Jayne Shaw**

Executive Chair

[jshaw@bcaldiagnostics.com](mailto:jshaw@bcaldiagnostics.com)

#### **Guy Robertson**

Chief Financial Officer

[grobertson@bcaldiagnostics.com](mailto:grobertson@bcaldiagnostics.com)

For personal use only